Dev Labtech Ventures Prepares for Major Corporate Overhaul

Dev Labtech Venture Limited's board of directors convened on March 27, 2026, approving a series of strategic financial moves designed to reshape its corporate structure and market presence. The company announced plans for a substantial capital increase, a stock split, a bonus share issuance, and a new term loan.

These initiatives are aimed at enhancing shareholder value, improving stock liquidity, and funding future growth. Specifically, the company is set to increase its authorized share capital by ₹10 crore and secure a ₹7.44 crore term loan from the Small Industries Development Bank of India (SIDBI) for potential expansion.

Board Approves Key Financial Actions

The proposed ₹10 crore capital increase will raise Dev Labtech's authorized share capital from ₹15 crore to ₹25 crore, granting it greater financial flexibility. The 1:2 stock split is designed to lower the face value of each equity share from ₹10 to ₹5, making the stock potentially more accessible to a broader investor base and boosting trading liquidity. Furthermore, a 1:1 bonus share issue will reward existing shareholders by doubling their holdings, funded from the company's reserves.

The planned ₹7.44 crore term loan from SIDBI, a key lender for micro, small, and medium enterprises, signals the company's intent to finance growth, operational upgrades, or strategic development.

Shareholder Approval Pending

All these strategic proposals are subject to the successful outcome of a shareholder vote via postal ballot. The company will proceed with the necessary regulatory compliances following shareholder consent.

Strategic Rationale Behind the Moves

The proposed stock split and bonus issue are intended to boost share liquidity and reward the company's existing investors. The capital increase and SIDBI loan signal a proactive management approach, aiming to strengthen the company's financial structure and support its growth trajectory within the healthcare and medical equipment sector.

Company and Lender Background

Dev Labtech Venture Limited focuses on manufacturing and trading diagnostic reagents, consumables, and instruments. SIDBI plays a crucial role in providing credit and support services to MSMEs across India.

Investor Implications

• Increased Financial Flexibility: Higher authorized capital allows for greater capacity for future fundraising or strategic capital allocation.
• Enhanced Share Liquidity: The 1:2 stock split is expected to lower the per-share price, potentially attracting more retail investors and increasing trading volumes.
• Shareholder Value Boost: The 1:1 bonus issue will double the number of shares held by existing shareholders, potentially improving investor sentiment.
• Growth Funding: The ₹7.44 crore term loan from SIDBI could be used for capital expenditure, R&D, or working capital needs, supporting business expansion.

Key Risks to Monitor

The primary risk is the company's dependence on shareholder approval for all planned corporate actions. A failure to secure the necessary votes could halt or significantly alter the strategic roadmap.

Industry Peers

Dev Labtech operates in the healthcare and medical equipment space, alongside peers such as Molbio Diagnostics Ltd and BPL Medical Technologies Ltd, companies also involved in diagnostics and medical device manufacturing.

Financial and Operational Details

• Authorized share capital will increase from ₹15 crore to ₹25 crore.
• Equity shares will be split in a 1:2 ratio, changing the face value from ₹10 to ₹5.
• The 1:1 bonus issue requires approximately ₹11.86 crore, funded by reserves of about ₹29.00 crore (as of March 31, 2025).
• A term loan facility of ₹7.44 crore is to be obtained from SIDBI.

Outlook and Next Steps

Investors will closely watch the outcome of the shareholder postal ballot. Key events to track include the official announcement of the record date for the bonus issue, the formal terms of the SIDBI loan agreement, and any company communications regarding the specific utilization of the loan funds. The completion of the stock split and bonus issue is estimated by May 25, 2026.